Oncoustics creates advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. By applying AI to raw ultrasound signals, Oncoustics rapidly differentiates healthy versus diseased tissues via novel acoustic biomarkers for virtual biopsy tools, surgical guidance and drug development. Their prospectively collected >4M+ pieces of data is the largest RF signal dataset in the world, creating an inimitable position. Initially targeting liver disease, a $60B+ global diagnostic market, Oncoustics is currently filing FDA submissions for the OnX liver assessment solution which has been introduced to over 70 clinics and hundreds of KOLs globally. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.